BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18083313)

  • 1. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes.
    Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 354(1-2):56-62. PubMed ID: 18083313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X; Ishida T; Kiwada H
    J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
    Ishida T; Atobe K; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes.
    Ishida T; Ichihara M; Wang X; Yamamoto K; Kimura J; Majima E; Kiwada H
    J Control Release; 2006 May; 112(1):15-25. PubMed ID: 16515818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice.
    Ishida T; Ichikawa T; Ichihara M; Sadzuka Y; Kiwada H
    J Control Release; 2004 Mar; 95(3):403-12. PubMed ID: 15023452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats.
    Wang XY; Ishida T; Ichihara M; Kiwada H
    J Control Release; 2005 May; 104(1):91-102. PubMed ID: 15866337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome].
    Ishida T; Kiwada H
    Yakugaku Zasshi; 2008 Feb; 128(2):233-43. PubMed ID: 18239370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes.
    Ishida T; Ichihara M; Wang X; Kiwada H
    J Control Release; 2006 Oct; 115(3):243-50. PubMed ID: 17011060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes.
    Koide H; Asai T; Hatanaka K; Akai S; Ishii T; Kenjo E; Ishida T; Kiwada H; Tsukada H; Oku N
    Int J Pharm; 2010 Jun; 392(1-2):218-23. PubMed ID: 20227473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes.
    Tagami T; Nakamura K; Shimizu T; Yamazaki N; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):160-6. PubMed ID: 19850094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats.
    Ishida T; Kashima S; Kiwada H
    J Control Release; 2008 Mar; 126(2):162-5. PubMed ID: 18160170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
    Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
    Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
    Taguchi K; Urata Y; Anraku M; Watanabe H; Kadowaki D; Sakai H; Horinouchi H; Kobayashi K; Tsuchida E; Maruyama T; Otagiri M
    Drug Metab Dispos; 2009 Nov; 37(11):2197-203. PubMed ID: 19679674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon.
    Shimizu T; Ishida T; Kiwada H
    Immunobiology; 2013 May; 218(5):725-32. PubMed ID: 22995937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
    Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
    Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase.
    Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Yang H
    J Pharm Pharmacol; 2008 Dec; 60(12):1651-7. PubMed ID: 19000370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
    Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
    J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes.
    Shimizu T; Abu Lila AS; Fujita R; Awata M; Kawanishi M; Hashimoto Y; Okuhira K; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2018 Jun; 127():142-149. PubMed ID: 29462689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Particle size-dependent triggering of accelerated blood clearance phenomenon.
    Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
    Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.